Amneal Intermediate Inc
NASDAQ:AMRX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.97
12.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Amneal Intermediate Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Amneal Intermediate Inc
NASDAQ:AMRX
|
3.9B USD |
12%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
996.3B USD |
44%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
512.5B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
255.3B CHF |
34%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.7B GBP |
24%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
205.1B CHF |
33%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
250.5B USD |
38%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
42%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
209B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
149B USD |
29%
|
Amneal Intermediate Inc
Glance View
Amneal Intermediate Inc. operates as a vital player within the pharmaceutical industry, bringing a unique blend of agility and scale to its business operations. Formed from the merger of Amneal Pharmaceuticals LLC and Impax Laboratories, the company has established a broad footprint in both generic and specialty pharmaceuticals. Amneal leverages its extensive manufacturing capabilities to produce a diverse portfolio of generic medications, which is not only cost-effective for patients but also represents a significant revenue stream. Its strategic approach lies in launching high-barrier-to-entry generics, ensuring that the products have minimal competition in the market. This strategy not only helps in capturing market share swiftly but also supports better pricing power. Alongside its robust generics division, Amneal invests substantially in its specialty segment. This arm of the company focuses on developing branded pharmaceuticals, particularly in therapeutic areas such as central nervous system disorders, endocrinology, and oncology. By placing strategic bets on these high-growth areas, Amneal aims to capture another layer of the lucrative pharmaceutical market. Its knack for identifying unmet medical needs and bringing timely, effective treatments to market highlights the company's commitment to innovation and patient care. Together, the combination of high-volume generic production and targeted specialty drug development creates a well-rounded business model designed to drive sustainable growth in a competitive industry.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Amneal Intermediate Inc's most recent financial statements, the company has Operating Margin of 12.3%.